Kyle Moran Sells 3,588 Shares of WAVE Life Sciences (NASDAQ:WVE) Stock

WAVE Life Sciences Ltd. (NASDAQ:WVE) CFO Kyle Moran sold 3,588 shares of the firm’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $13.45, for a total value of $48,258.60. Following the sale, the chief financial officer owned 134,385 shares of the company’s stock, valued at $1,807,478.25. This represents a 2.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Kyle Moran also recently made the following trade(s):

• On Tuesday, December 9th, Kyle Moran sold 50,036 shares of WAVE Life Sciences stock. The stock was sold at an average price of $20.03, for a total value of $1,002,221.08.
• On Monday, December 8th, Kyle Moran sold 210,000 shares of WAVE Life Sciences stock. The shares were sold at an average price of $14.77, for a total value of $3,101,700.00.

WAVE Life Sciences Trading Down 2.4%

NASDAQ WVE traded down $0.32 during mid-day trading on Wednesday, reaching $13.27. 2,543,164 shares of the company’s stock traded hands, compared to its average volume of 3,266,049. WAVE Life Sciences Ltd. has a 1-year low of $5.28 and a 1-year high of $21.73. The company has a fifty day simple moving average of $14.99 and a 200-day simple moving average of $10.38. The company has a market cap of $2.22 billion, a price-to-earnings ratio of -17.69 and a beta of -1.78.

WAVE Life Sciences (NASDAQ:WVE) last released its earnings results on Monday, November 10th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.02). The business had revenue of $7.61 million for the quarter, compared to analysts’ expectations of $9.85 million. WAVE Life Sciences had a negative net margin of 111.64% and a negative return on equity of 75.61%. Equities research analysts forecast that WAVE Life Sciences Ltd. will post -1.14 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on WVE shares. Weiss Ratings reissued a “sell (d-)” rating on shares of WAVE Life Sciences in a report on Wednesday, January 21st. Cantor Fitzgerald increased their price target on shares of WAVE Life Sciences from $34.00 to $41.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Morgan Stanley set a $28.00 price target on WAVE Life Sciences in a research note on Monday, December 8th. Wall Street Zen lowered WAVE Life Sciences from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Raymond James Financial reaffirmed an “outperform” rating and set a $21.00 target price on shares of WAVE Life Sciences in a report on Monday, December 8th. Fourteen investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $32.69.

Institutional Trading of WAVE Life Sciences

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. CWM LLC boosted its position in WAVE Life Sciences by 6,729.0% during the 4th quarter. CWM LLC now owns 2,117 shares of the company’s stock valued at $36,000 after purchasing an additional 2,086 shares during the period. Bessemer Group Inc. lifted its stake in WAVE Life Sciences by 1,156.3% in the third quarter. Bessemer Group Inc. now owns 9,925 shares of the company’s stock valued at $72,000 after buying an additional 9,135 shares during the last quarter. Russell Investments Group Ltd. lifted its stake in WAVE Life Sciences by 1,441.6% in the third quarter. Russell Investments Group Ltd. now owns 9,928 shares of the company’s stock valued at $73,000 after buying an additional 9,284 shares during the last quarter. Ameritas Investment Partners Inc. boosted its holdings in shares of WAVE Life Sciences by 18.7% during the second quarter. Ameritas Investment Partners Inc. now owns 11,444 shares of the company’s stock valued at $74,000 after acquiring an additional 1,802 shares during the period. Finally, Tower Research Capital LLC TRC grew its position in shares of WAVE Life Sciences by 44.8% during the second quarter. Tower Research Capital LLC TRC now owns 11,658 shares of the company’s stock worth $76,000 after acquiring an additional 3,609 shares during the last quarter. 89.73% of the stock is currently owned by institutional investors and hedge funds.

WAVE Life Sciences Company Profile

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.